[go: up one dir, main page]

MA31768B1 - Formulations galeniques de composes organiques - Google Patents

Formulations galeniques de composes organiques

Info

Publication number
MA31768B1
MA31768B1 MA32758A MA32758A MA31768B1 MA 31768 B1 MA31768 B1 MA 31768B1 MA 32758 A MA32758 A MA 32758A MA 32758 A MA32758 A MA 32758A MA 31768 B1 MA31768 B1 MA 31768B1
Authority
MA
Morocco
Prior art keywords
organic compounds
dosage formulations
dosage form
oral dosage
relates
Prior art date
Application number
MA32758A
Other languages
Arabic (ar)
English (en)
Inventor
Jean-Claude Bianchi
Heiko Busies
Andreas Meyer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31768(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31768B1 publication Critical patent/MA31768B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur une forme posologique orale solide compactée au rouleau comprenant une quantité thérapeutiquement efficace d'aliskirène, ou d'un sel pharmaceutiquement acceptable de celui-ci, l'ingrédient actif étant présent dans une quantité de plus de 38 % en poids sur la base du poids total de la forme posologique orale. L'invention porte également sur un procédé de préparation de ladite forme posologique orale solide.
MA32758A 2007-09-28 2010-04-08 Formulations galeniques de composes organiques MA31768B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97589407P 2007-09-28 2007-09-28
PCT/EP2008/062769 WO2009040373A2 (fr) 2007-09-28 2008-09-24 Formulations galéniques de composés organiques

Publications (1)

Publication Number Publication Date
MA31768B1 true MA31768B1 (fr) 2010-10-01

Family

ID=40377181

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32758A MA31768B1 (fr) 2007-09-28 2010-04-08 Formulations galeniques de composes organiques

Country Status (22)

Country Link
US (1) US20110033533A1 (fr)
EP (2) EP2205232A2 (fr)
JP (1) JP5378384B2 (fr)
KR (1) KR20100076996A (fr)
CN (1) CN101808630A (fr)
AR (1) AR068539A1 (fr)
AU (1) AU2008303504C1 (fr)
BR (1) BRPI0817586A2 (fr)
CA (1) CA2697229A1 (fr)
CL (1) CL2008002828A1 (fr)
CO (1) CO6270216A2 (fr)
GT (1) GT201000064A (fr)
MA (1) MA31768B1 (fr)
MX (1) MX2010003260A (fr)
MY (1) MY148266A (fr)
NZ (1) NZ584005A (fr)
PE (1) PE20091203A1 (fr)
RU (1) RU2483718C2 (fr)
TN (1) TN2010000120A1 (fr)
TW (1) TWI436760B (fr)
WO (1) WO2009040373A2 (fr)
ZA (1) ZA201001144B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520984A (ja) * 2008-05-23 2011-07-21 テバ ファーマシューティカル インダストリーズ リミティド アリスキレンモノフマル酸塩及びその製造方法
WO2011116115A1 (fr) 2010-03-16 2011-09-22 Novartis Ag Composition d'aliskiren comprenant un acide gras à chaîne moyenne et procédé de fabrication correspondant
TR201002256A1 (tr) 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
US20110268797A1 (en) 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
RU2183116C1 (ru) * 2001-07-10 2002-06-10 Жаров Олег Владимирович Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
US20050220865A1 (en) * 2004-04-02 2005-10-06 Koleng John J Compressed composition comprising magnesium salt
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
BRPI0609915A2 (pt) * 2005-04-27 2010-05-25 Novartis Ag métodos para tratar aterosclerose
US20080261958A1 (en) * 2005-11-08 2008-10-23 Randy Lee Webb Combination of Organic Compounds
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1891937A1 (fr) * 2006-08-25 2008-02-27 Novartis AG Formulations galéniques de l'aliskiren
JP2010509254A (ja) * 2006-11-09 2010-03-25 ノバルティス アーゲー アリスキレンとオロチン酸の塩
EP1972335A1 (fr) * 2007-03-23 2008-09-24 Krka Formes de dosage solide comportant de l'aliskiren et ses sels pharmaceutiques acceptables
AU2008309058B2 (en) * 2007-09-28 2012-08-09 Novartis Ag Galenical formulations of Aliskiren and Valsartan

Also Published As

Publication number Publication date
RU2010116530A (ru) 2011-11-10
EP2548553A1 (fr) 2013-01-23
BRPI0817586A2 (pt) 2015-03-31
CL2008002828A1 (es) 2009-05-15
AU2008303504B2 (en) 2012-03-22
AR068539A1 (es) 2009-11-18
TW200922546A (en) 2009-06-01
RU2483718C2 (ru) 2013-06-10
TN2010000120A1 (en) 2011-09-26
MX2010003260A (es) 2010-04-29
EP2205232A2 (fr) 2010-07-14
WO2009040373A2 (fr) 2009-04-02
WO2009040373A3 (fr) 2009-08-20
ZA201001144B (en) 2011-12-28
CA2697229A1 (fr) 2009-04-02
AU2008303504C1 (en) 2013-05-16
PE20091203A1 (es) 2009-09-11
NZ584005A (en) 2012-08-31
KR20100076996A (ko) 2010-07-06
JP2010540489A (ja) 2010-12-24
TWI436760B (zh) 2014-05-11
MY148266A (en) 2013-03-29
CO6270216A2 (es) 2011-04-20
AU2008303504A1 (en) 2009-04-02
CN101808630A (zh) 2010-08-18
US20110033533A1 (en) 2011-02-10
GT201000064A (es) 2012-03-30
JP5378384B2 (ja) 2013-12-25

Similar Documents

Publication Publication Date Title
MY144477A (en) Galenic formulations of organic compounds
WO2010068810A3 (fr) Amides substitués, et leurs procédés de production et d'utilisation
NZ584686A (en) Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate
GEP20084527B (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
MA32787B1 (fr) Peptides antiviraux therapeutiques
TN2009000160A1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoides
MA31768B1 (fr) Formulations galeniques de composes organiques
MA32964B1 (fr) Formulation a effet retard d'octreotide avec niveau d'exposition constamment eleves
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
MA28514B1 (fr) Formulations pharmaceutiques pour inhalateur de poudre seche comprenant un principe actif agissant meme a faible dosage
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
WO2005058890A3 (fr) Derives d'hydronopol utilises comme agonistes des recepteurs orl1 humains
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
WO2006009789A3 (fr) Derives piperazine a substitution aryle
GEP20084519B (en) 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors
WO2009007137A3 (fr) Composition pharmaceutique pour application topique de composés difficilement solubles
WO2007125398A3 (fr) Sulfonamides
MA33166B1 (fr) Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
UA88943C2 (ru) Быстрый способ влажного гранулирования для получения композиций, которые содержат кальций
GEP20094680B (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
MA33619B1 (fr) Agent thérapeutique pour des troubles de l'anxiété
WO2008065144A3 (fr) Préparations galéniques de composés organiques
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors